REFERENCES
2. Patel AP, Fisher JL, Nichols E, Abd-allah F, Abdela J, et al. Global, regional, and national burden of brain and other CNS cancer, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019;18:376-93.
3. Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro Oncol 2019;21:v1-100.
4. Smith MA, Reaman GH. Remaining challenges in childhood cancer and newer targeted therapeutics. Pediatr Clin North Am 2015;62:301-12.
5. Perus LJM, Walsh LA. Microenvironmental Heterogeneity in Brain Malignancies. Front Immunol 2019;10:2294.
6. Gupta A, Dwivedi T. A simplified overview of world health organization classification update of central nervous system tumors 2016. J Neurosci Rural Pract 2017;8:629-41.
7. Claus EB, Walsh KM, Wiencke JK, Molinaro AM, Wiemels JL, et al. Survival and low-grade glioma: the emergence of genetic information. Neurosurg Focus 2015;38:E6.
8. Rasmussen BK, Hansen S, Laursen RJ, Kosteljanetz M, Schultz H, et al. Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry. J Neurooncol 2017;135:571-9.
9. Barnholtz-Sloan JS, Ostrom QT, Cote D. Epidemiology of brain tumors. Neurol Clin 2018;36:395-419.
10. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
11. Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, et al. Challenges to curing primary brain tumours. Nat Rev Clin Oncol 2019;16:509-20.
12. Hambardzumyan D, Gutmann DH, Kettenmann H. The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci 2016;19:20-7.
14. Gerstner ER, Fine RL. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 2007;25:2306-12.
15. Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, et al. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro Oncol 2018;20:184-91.
16. Zhang F, Stephan SB, Ene CI, Smith TT, Holland EC, et al. Nanoparticles that reshape the tumor milieu create a therapeutic window for effective T-cell therapy in solid malignancies. Cancer Res 2018;78:3718-30.
17. Le Rhun E, Preusser M, Roth P, Reardon DA, van den Bent M, et al. Molecular targeted therapy of glioblastoma. Cancer Treat Rev 2019;80:101896.
18. Durand T, Bernier MO, Léger I, Taillia H, Noël G, et al. Cognitive outcome after radiotherapy in brain tumor. Curr Opin Oncol 2015;27:510-5.
19. Brinkman TM, Krasin MJ, Liu W, Armstrong GT, Ojha RP, et al. Long-term neurocognitive functioning and social attainment in adult survivors of pediatric CNS tumors: results from the St Jude lifetime cohort study. J Clin Oncol 2016;34:1358-67.
20. American Cancer Society. Cancer Facts & Figures 2019. Available from: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2019.html. [Last accessed on 2 Sep 2020].
21. Schläger C, Körner H, Krueger M, Vidoli S, Haberl M, et al. Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid. Nature 2016;530:349-53.
22. Louveau A, Herz J, Alme MN, Salvador AF, Dong MQ, et al. CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature. Nat Neurosci 2018;21:1380-91.
23. Weber JS, D’angelo SP, Minor D, Hodi FS, Gutzmer R, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16:375-84.
24. Gubens MA, Sequist LV, Stevenson JP, Powell SF, Villaruz LC, et al. Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H. Lung Cancer 2019;130:59-66.
25. Shanafelt TD, Wang XV, Kay NE, Hanson CA, O’Brien S, et al. Ibrutinib-Rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med 2019;381:432-43.
26. Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 2018;19:672-81.
27. Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med 2019;25:477-86.
28. Westphal M, Heese O, Steinbach JP, Schnell O, Schackert G, et al. A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. Eur J Cancer 2015;51:522-32.
29. Reardon DA, Omuro A, Brandes AA, Rieger J, Wick A, et al. OS10.3 randomized phase 3 study evaluating the efficacy and safety of Nivolumab vs Bevacizumab in patients with recurrent glioblastoma: CheckMate 143. Neuro-Oncology 2017;19:iii21-2.
30. Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol 2018;20:674-86.
31. Ferreri AJM, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 2016;3:e217-27.
32. Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, et al. First results on survival from a large phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med 2018;16:142.
33. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013;19:1423-37.
34. Bejoy J, Yuan X, Song L, Hua T, Jeske R, et al. Genomics analysis of metabolic pathways of human stem cell-derived microglia-like cells and the integrated cortical spheroids. Stem Cells Int 2019;2019:2382534.
35. Griffin K, Bejoy J, Song L, Hua T, Marzano M, et al. Human stem cell-derived aggregates of forebrain astroglia respond to amyloid beta oligomers. Tissue Eng Part A 2020;26:527-42.
36. Song L, Yuan X, Jones Z, Vied C, Miao Y, et al. Functionalization of brain region-specific spheroids with isogenic microglia-like cells. Sci Rep 2019;9:11055.
37. Chen W, Wang D, Du X, He Y, Chen S, et al. Glioma cells escaped from cytotoxicity of temozolomide and vincristine by communicating with human astrocytes. Med Oncol 2015;32:43.
38. Venkatesh HS, Johung TB, Caretti V, Noll A, Tang Y, et al. Neuronal activity promotes glioma growth through neuroligin-3 secretion. Cell 2015;161:803-16.
39. Galvao RP, Kasina A, McNeill RS, Harbin JE, Foreman O, et al. Transformation of quiescent adult oligodendrocyte precursor cells into malignant glioma through a multistep reactivation process. Proc Natl Acad Sci U S A 2014;111:E4214-23.
40. Hide T, Shibahara I, Kumabe T. Novel concept of the border niche: glioblastoma cells use oligodendrocytes progenitor cells (GAOs) and microglia to acquire stem cell-like features. Brain Tumor Pathol 2019;36:63-73.
42. Henrik Heiland D, Ravi VM, Behringer SP, Frenking JH, Wurm J, et al. Tumor-associated reactive astrocytes aid the evolution of immunosuppressive environment in glioblastoma. Nat Commun 2019;10:2541.
43. Hide T, Komohara Y, Miyasato Y, Nakamura H, Makino K, et al. Oligodendrocyte progenitor cells and macrophages/microglia produce glioma stem cell niches at the tumor border. EBioMedicine 2018;30:94-104.
44. Azambuja JH, da Silveira EF, de Carvalho TR, Oliveira PS, Pacheco S, et al. Glioma sensitive or chemoresistant to temozolomide differentially modulate macrophage protumor activities. Biochim Biophys Acta Gen Subj 2017;1861:2652-62.
45. Chang AL, Miska J, Wainwright DA, Dey M, Rivetta CV, et al. CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells. Cancer Res 2016;76:5671-82.
46. Domenis R, Cesselli D, Toffoletto B, Bourkoula E, Caponnetto F, et al. Systemic T cells immunosuppression of glioma stem cell-derived exosomes is mediated by monocytic myeloid-derived suppressor cells. PLoS One 2017;12:e0169932.
47. Li Z, Liu X, Guo R, Wang P. CD4+Foxp3- type 1 regulatory T cells in glioblastoma multiforme suppress T cell responses through multiple pathways and are regulated by tumor-associated macrophages. Int J Biochem Cell Biol 2016;81:1-9.
48. Frei K, Gramatzki D, Tritschler I, Schroeder JJ, Espinoza L, et al. Transforming growth factor-β pathway activity in glioblastoma. Oncotarget 2015;6:5963-77.
49. Mostafa H, Pala A, Högel J, Hlavac M, Dietrich E, et al. Immune phenotypes predict survival in patients with glioblastoma multiforme. J Hematol Oncol 2016;9:77.
50. Tamura R, Tanaka T, Akasaki Y, Murayama Y, Yoshida K, et al. The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications. Med Oncol 2019;37:2.
51. Valdor R, García-Bernal D, Riquelme D, Martinez CM, Moraleda JM, et al. Glioblastoma ablates pericytes antitumor immune function through aberrant up-regulation of chaperone-mediated autophagy. Proc Natl Acad Sci U S A 2019;116:20655-65.
52. Guo X, Xue H, Shao Q, Wang J, Guo X, et al. Hypoxia promotes glioma-associated macrophage infiltration via periostin and subsequent M2 polarization by upregulating TGF-beta and M-CSFR. Oncotarget 2016;7:80521-42.
53. Friebel E, Kapolou K, Unger S, Núñez NG, Utz S, et al. Single-cell mapping of human brain cancer reveals tumor-specific instruction of tissue-invading leukocytes. Cell 2020;181:1626-42.e20.
54. Klemm F, Maas RR, Bowman RL, Kornete M, Soukup K, et al. Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells. Cell 2020;181:1643-60.e17.
55. Drachsler M, Kleber S, Mateos A, Volk K, Mohr N, et al. CD95 maintains stem cell-like and non-classical EMT programs in primary human glioblastoma cells. Cell Death Dis 2016;7:e2209.
56. Ge H, Mu L, Jin L, Yang C, Chang YE, et al. Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM. Int J Cancer 2017;141:1434-44.
57. Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim CK, et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res 2014;20:5290-301.
58. Wainwright DA, Balyasnikova IV, Chang AL, Ahmed AU, Moon KS, et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res 2012;18:6110-21.
59. Abou-Ghazal M, Yang DS, Qiao W, Reina-Ortiz C, Wei J, et al. The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res 2008;14:8228-35.
60. Piperi C, Papavassiliou KA, Papavassiliou AG. Pivotal Role of STAT3 in shaping glioblastoma immune microenvironment. Cells 2019;8:1398.
61. Yan J, Kong LY, Hu J, Gabrusiewicz K, Dibra D, et al. FGL2 as a multimodality regulator of tumor-mediated immune suppression and therapeutic target in gliomas. J Natl Cancer Inst 2015;107:djv137.
62. Yan J, Zhao Q, Gabrusiewicz K, Kong LY, Xia X, et al. FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation. Nat Commun 2019;10:448.
63. Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 2017;545:495-9.
64. Davidson TB, Lee A, Hsu M, Sedighim S, Orpilla J, et al. Expression of PD-1 by T cells in malignant glioma patients reflects exhaustion and activation. Clin Cancer Res 2019;25:1913-22.
65. Fecci PE, Sampson JH. The current state of immunotherapy for gliomas: an eye toward the future. J Neurosurg 2019;131:657-66.
66. Darmanis S, Sloan SA, Croote D, Mignardi M, Chernikova S, et al. Single-cell RNA-Seq analysis of infiltrating neoplastic cells at the migrating front of human glioblastoma. Cell Rep 2017;21:1399-410.
67. Zhao Y, Yang W, Huang Y, Cui R, Li X, et al. Evolving roles for targeting CTLA-4 in cancer immunotherapy. Cell Physiol Biochem 2018;47:721-34.
68. Maxwell R, Jackson CM, Lim M. Clinical trials investigating immune checkpoint blockade in glioblastoma. Curr Treat Options Oncol 2017;18:51.
70. Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol 2017;8:561.
71. Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, et al. A new member of the immunoglobulin superfamily--CTLA-4. Nature 1987;328:267-70.
72. Romani M, Pistillo MP, Carosio R, Morabito A, Banelli B. Immune checkpoints and innovative therapies in glioblastoma. Front Oncol 2018;8:464.
73. Chen C, Rowell EA, Thomas RM, Hancock WW, Wells AD. Transcriptional regulation by Foxp3 is associated with direct promoter occupancy and modulation of histone acetylation. J Biol Chem 2006;281:36828-34.
74. Simonelli M, Persico P, Perrino M, Zucali PA, Navarria P, et al. Checkpoint inhibitors as treatment for malignant gliomas: “A long way to the top”. Cancer Treat Rev 2018;69:121-31.
75. Tsui K, Gajjar A, Li C, Srivastava D, Broniscer A, et al. Subsequent neoplasms in survivors of childhood central nervous system tumors: risk after modern multimodal therapy. Neuro Oncol 2015;17:448-56.
76. Chen RQ, Liu F, Qiu XY, Chen XQ. The prognostic and therapeutic value of PD-L1 in Glioma. Front Pharmacol 2018;9:1503.
77. Hwang K, Koh EJ, Choi EJ, Kang TH, Han JH, et al. PD-1/PD-L1 and immune-related gene expression pattern in pediatric malignant brain tumors: clinical correlation with survival data in Korean population. J Neurooncol 2018;139:281-91.
78. Liu F, Huang J, Liu X, Cheng Q, Luo C, et al. CTLA-4 correlates with immune and clinical characteristics of glioma. Cancer Cell Int 2020;20:7.
79. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.
80. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, et al. Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123-35.
81. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, et al; CheckMate 025 Investigators. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1803-13.
82. Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 2016;17:976-83.
83. Reiss SN, Yerram P, Modelevsky L, Grommes C. Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas. J Immunother Cancer 2017;5:99.
84. Chamberlain MC, Kim BT. Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series. J Neurooncol 2017;133:561-9.
85. Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, López-Janeiro A, Porciuncula A, et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat Med 2019;25:470-6.
86. Reardon DA, Kim T, Frenel J, Santoro A, Lopez J, et al. ATIM-35. Results of the phase IB keynote-028 multi-cohort trial of pembrolizumab monotherapy in patients with recurrent PD-L1-positive glioblastoma multiforme (GBM). Neuro-Oncology 2016;18:vi25-6.
87. Ardon H, Van Gool SW, Verschuere T, Maes W, Fieuws S, et al. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol Immunother 2012;61:2033-44.
88. Chang CN, Huang YC, Yang DM, Kikuta K, Wei KJ, et al. A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma. J Clin Neurosci 2011;18:1048-54.
89. Schmittling RJ, Archer GE, Mitchell DA, Heimberger A, Pegram C, et al. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. J Immunol Methods 2008;339:74-81.
90. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010;28:4722-9.
91. Suto R, Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 1995;269:1585-8.
92. Ji N, Zhang Y, Liu Y, Xie J, Wang Y, et al. Heat shock protein peptide complex-96 vaccination for newly diagnosed glioblastoma: a phase I, single-arm trial. JCI Insight 2018;3:99145.
93. Bloch O, Crane CA, Fuks Y, Kaur R, Aghi MK, et al. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol 2014;16:274-9.
94. Yu JS, Liu G, Ying H, Yong WH, Black KL, et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004;64:4973-9.
95. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005;11:5515-25.
96. Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tønnesen P, et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother 2013;62:1499-509.
97. Fadul CE, Fisher JL, Hampton TH, Lallana EC, Li Z, et al. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother 2011;34:382-9.
98. Frank MO, Kaufman J, Parveen S, Blachère NE, Orange DE, et al. Dendritic cell vaccines containing lymphocytes produce improved immunogenicity in patients with cancer. J Transl Med 2014;12:338.
99. Wen PY, Reardon DA, Armstrong TS, Phuphanich S, Aiken RD, et al. A randomized double-blind placebo-controlled phase II trial of dendritic cell vaccine ICT-107 in newly diagnosed patients with glioblastoma. Clin Cancer Res 2019;25:5799-807.
100. Brown MP, Ebert LM, Gargett T. Clinical chimeric antigen receptor-T cell therapy: a new and promising treatment modality for glioblastoma. Clin Transl Immunology 2019;8:e1050.
101. Neidert MC, Kowalewski DJ, Silginer M, Kapolou K, Backert L, et al. The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy. Acta Neuropathol 2018;135:923-38.
102. Brown CE, Starr R, Aguilar B, Shami AF, Martinez C, et al. Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells. Clin Cancer Res 2012;18:2199-209.
103. Pituch KC, Miska J, Krenciute G, Panek WK, Li G, et al. Adoptive transfer of IL13Rα2-specific chimeric antigen receptor t cells creates a pro-inflammatory environment in glioblastoma. Mol Ther 2018;26:986-95.
104. Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med 2016;375:2561-9.
105. Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med 2016;375:2561-9.
106. O’Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med 2017;9:eaaa0984.
107. Goff SL, Morgan RA, Yang JC, Sherry RM, Robbins PF, et al. Pilot trial of adoptive transfer of chimeric antigen receptor-transduced T cells targeting EGFRvIII in patients with glioblastoma. J Immunother 2019;42:126-35.
108. Ahmed N, Brawley V, Hegde M, Bielamowicz K, Wakefield A, et al. Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial. J Immunotherapy Cancer 2015;3.
109. Akhavan D, Alizadeh D, Wang D, Weist MR, Shepphird JK, et al. CAR T cells for brain tumors: lessons learned and road ahead. Immunol Rev 2019;290:60-84.
110. Chow VA, Gopal AK, Maloney DG, Turtle CJ, Smith SD, et al. Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy. Am J Hematol 2019;94:E209-E213.
111. Majd N, Dasgupta P, de Groot J. Immunotherapy for neuro-oncology. Adv Exp Med Biol 2020;1244:183-203.
112. Wang W, Jiang J, Wu C. CAR-NK for tumor immunotherapy: clinical transformation and future prospects. Cancer Lett 2020;472:175-80.
113. Burger MC, Zhang C, Harter PN, Romanski A, Strassheimer F, et al. CAR-engineered NK cells for the treatment of glioblastoma: turning innate effectors into precision tools for cancer immunotherapy. Front Immunol 2019;10:2683.
114. Kruse CA, Cepeda L, Owens B, Johnson SD, Stears J, et al. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother 1997;45:77-87.
115. Dillman RO, Duma CM, Ellis RA, Cornforth AN, Schiltz PM, et al. Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma. J Immunother 2009;32:914-9.
116. Plautz GE, Barnett GH, Miller DW, Cohen BH, Prayson RA, et al. Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg 1998;89:42-51.
117. Mondal M, Guo J, He P, Zhou D. Recent advances of oncolytic virus in cancer therapy. Hum Vaccin Immunother 2020:1-14.
118. Maxwell R, Luksik AS, Garzon-Muvdi T, Lim M. The potential of cellular- and viral-based immunotherapies for malignant glioma-dendritic cell vaccines, adoptive cell transfer, and oncolytic viruses. Curr Neurol Neurosci Rep 2017;17:50.
119. Martínez-Vélez N, Garcia-Moure M, Marigil M, González-Huarriz M, Puigdelloses M, et al. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. Nat Commun 2019;10:2235.
120. Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R, et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol 2018;36:1419-27.
122. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000;7:867-74.
123. Geletneky K, Hajda J, Angelova AL, Leuchs B, Capper D, et al. Oncolytic H-1 Parvovirus shows safety and signs of immunogenic activity in a first phase I/IIa glioblastoma trial. Mol Ther 2017;25:2620-34.
124. Reardon DA, Kaley TJ, Dietrich J, Clarke JL, Dunn G, et al. Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM). JCO 2019;37:2032.
125. Neyns B, Ben Salama L, Awada G, De Cremer J, Schwarze JK, et al. GLIAVAX: a stratified phase II clinical trial of avelumab and axitinib in patients with recurrent glioblastoma. JCO 2019;37:2034.
126. Reardon DA, Nayak L, Peters KB, Clarke JL, Jordan JT, et al. Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients. JCO 2018;36:2006.
127. Inogés S, Tejada S, de Cerio AL, Gállego Pérez-Larraya J, Espinós J, et al. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients. J Transl Med 2017;15:104.
128. Kong DS, Nam DH, Kang SH, Lee JW, Chang JH, et al. Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea. Oncotarget 2017;8:7003-13.
129. Migliorini D, Dutoit V, Allard M, Grandjean Hallez N, Marinari E, et al. Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients. Neuro Oncol 2019;21:923-33.
130. Sloan AE, Dansey R, Zamorano L, Barger G, Hamm C, et al. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Neurosurg Focus 2000;9:e9.
131. Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol 2011;13:324-33.
132. Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol 2015;17:854-61.
133. Weller M, Butowski N, Tran DD, Recht LD, Lim M, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol 2017;18:1373-85.
134. Reardon DA, Desjardins A, Vredenburgh JJ, O’Rourke DM, Tran DD, et al; ReACT trial investigators. Rindopepimut with Bevacizumab for Patients with relapsed EGFRvIII-expressing glioblastoma (ReACT): results of a double-blind randomized phase II trial. Clin Cancer Res 2020;26:1586-94.
